Conduct of the Trial Sample Clauses

Conduct of the Trial. 2.1 UCL and CTC shall undertake the Trial as Sponsor according to the approved Protocol, the Regulations, GCP and any other applicable local laws and regulations.
Sample 1Sample 2
AutoNDA by SimpleDocs
Conduct of the Trial. 1.1 The INSTITUTION and INVESTIGATOR each agree to perform the clinical trial in strict accordance with the protocol entitled, “ .” STUDY, dated 29 May 2014, which vlastní know-how a technické informace o takových produktech a prostředcích. VZHLEDEM K TOMU, ŽE ZADAVATEL najalklinickou výzkumnou organizaci Pharmaceutical Research Associates International („CRO”), aby jednala jako nezávislý dodavatel, ale ne jako strana této SMLOUVY, jménem ZADAVATELE za účelem provedení určitých aspektů úkolů ZADAVATELE uvedených níže, jako například splnění SMLOUVY, zaplacení, monitorování a/nebo jiné činnosti v rámci STUDIE; a VZHLEDEM K TOMU, ŽE společnost UCB BIOSCIENCES, INC. je jmenována ZADAVATELEM STUDIE (jak je definováno níže) a delegovala odpovědnost za provádění takové STUDIE na svoji SESTERSKOU SPOLEČNOST UCB BIOSCIENCES GMBH která xx xxxx označována jako ZADAVATEL pro účely této SMLOUVY; a VZHLEDEM K TOMU, ŽE si ZADAVATELpřeje zmocnit INSTITUCI k organizování a provedení („STUDOVANÝ LÉK“). („STUDIE“); a VZHLEDEM K TOMU, ŽE ŘEŠITEL jezaměstnán INSTITUCÍ a bude působit jako ŘEŠITEL pro STUDII (definováno výše); a VZHLEDEM K TOMU, ŽE INSTITUCE aŘEŠITEL přezkoumali dostatečné množství informací týkajících se STUDOVANÉHO LÉKU a PROTOKOL (definováno níže) pro vyhodnocení jejich zájmu o účast na STUDII. PROTO NYNÍ STRANY v úmyslu být právně vázány uzavřely tuto SMLOUVU a domluvily se zvláště na následujícím: 1. PROVEDENÍ HODNOCENÍ 1.1 INSTITUCE a ŘEŠITEL se zavazují každý zvlášť provést klinické hodnocení v přísném souladu s protokolem pod názvem „“ STUDIE , ze dne 29 května
Sample 1
Conduct of the Trial. The parties shall conduct the Trial on or before the date agreed upon.
Sample 1
Conduct of the Trial. The Institution, through the applicable Principal Investigator and Sub- investigators, shall use reasonable efforts to conduct each Trial in accordance with this Agreement, the applicable SOW, the applicable Protocol, and the applicable investigator’s brochure for the Protocol (the “Investigator’s Brochure”), as each may be amended, and all applicable United States laws, rules, regulations and guidelines, as adopted into law relating to the conduct of clinical investigations, good clinical practice (GCP) principles, generally accepted medical practice, and applicable export control rules and regulations (collectively, “Applicable Laws”). For purposes of this Agreement, the term “Institution” shall include all employees, executives, officers, directors, faculty, staff and other authorized agents of the Institution. SPONSOR will use reasonable efforts to perform its applicable obligations in connection with each Trial including, but not limited to, monitoring visits. Initiation of a Protocol under a SOW shall not begin until IRB (defined in Section 6.2) approval is obtained. SPONSOR and Institution shall consider each Trial under a respective SOW to be complete and concluded at all sites at such time as the occurrence of final data lock or earlier termination by a Data Safety Monitoring Board (“Trial Conclusion”). Sponsor shall conduct its obligations under this Agreement and each Trial in accordance with Applicable Laws.
Sample 1
Conduct of the Trial. Institution shall, and shall cause Principal Investigator and all Institution Personnel to, diligently perform the Trial in accordance with (i) the Protocol, (ii) Applicable Law, (iii) Sponsor’s or its designee’s written instructions and (iv) Institution’s internal policies (which policies Institution represents and warrants are not inconsistent with any of the foregoing). For purposes of this Agreement, “Applicable Law” shall mean all applicable laws, rules, and regulations pertaining to the activities contemplated herein, including without limitation, Directive 2001/20/EC, as implemented in the Czech Republic and as replaced by the CTR as soon as applicable, and Regulation (EU) 2016/679 of 2.1
Sample 1
Conduct of the Trial. The Sponsor and the CI shall undertake the Trial according to the approved Protocol, the Regulations, GCP (which, for clarity, refers to the principles of ICH Harmonised Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) as set out in Schedule 1 (Conditions and Principles of Good Clinical Practice and for the Protection of Clinical Trial Subjects) of the Medicines for Human Use (Clinical Trials) Regulations 2004 and the GCP Directive 2005/28/EC, as set out in SI 2006/1928, and any amendments thereto), and any local laws and regulations applicable to clinical trials and the care of clinical trial subjects. The Trial shall be conducted by the CI: In all participating site(s) selected by the CI, with Sponsor oversight of site feasibility requirements; In accordance with the approved Protocol and any amendment/ modifications to the Protocol (unless urgent safety measures are deemed necessary); In accordance with the terms of the clinical trial authorisation (CTA) granted by the regulatory authority (MHRA); In accordance with the terms and conditions of the [REC]/[GTAC](delete what is not applicable) approval given to the Trial; In accordance with the relevant safety reporting provisions, as further described in this Agreement and the approved Protocol. In accordance with the applicable Sponsor SOPs for CTIMPs as amended from time to time and available on the JRO web site. The Parties acknowledge that the CI is expected to comply with their obligations under this Agreement as of its effective date in accordance with clause 4.1. Notwithstanding the foregoing, the CI is expected to comply with as many obligations as possible if the Trial has been set up prior to the effective date of this Agreement. The Parties shall comply with all UK laws and statutes applicable to the performance of clinical trials including, but not limited to, the Human Rights Act 1998, the Data Protection Act 1998, The Freedom of Information Act 2000, EU Regulations on Advanced Therapy Medicinal Products (delete if not an ATMP Trial), The EU Tissues and Cell Directive (delete if not an ATMP Trial involving procurement of tissues or cells), The Human Tissue Act 2004, the Regulations (as previously defined), GMP (which, for clarity, refers to refers to European Commission Directive 2003/94/EC laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use, and any amendm...
Sample 1
Conduct of the Trial. 2. Provádění studie.
Sample 1
AutoNDA by SimpleDocs
Conduct of the Trial 
Sample 1Sample 2Sample 3See All (7)

Related to Conduct of the Trial

  • Conduct of the Business Each of the Company and Parent covenants and agrees that:

  • Conduct of the Company’s Business The Company covenants and agrees that, prior to the Effective Time, unless Parent shall otherwise consent in writing or as otherwise expressly contemplated by this Agreement:

  • Conduct of the Company Except (t) with the prior written consent of Parent (which consent shall not be unreasonably withheld, conditioned or delayed), (u) as expressly permitted, required or contemplated by this Agreement, (v) as set forth in Section 6.01 of the Company Disclosure Schedule, (w) as required by Applicable Law, (x) pursuant to the terms of any Company Plan in effect as of the date hereof, (y) in connection with any reasonable action taken, or omitted to be taken, pursuant to any COVID-19 Measures or which is otherwise taken, or omitted to be taken, in reasonable response to COVID-19 in good faith, from the date hereof until the Effective Time (provided that the Company shall consult if legally permissible with Parent in good faith prior to taking such actions to the extent reasonably practicable under the circumstances), or (z) as expressly required or contemplated by any Contract between the Company or any of its Subsidiaries, on the one hand, and ONE or any of its Affiliates, on the other hand, the Company (a) shall, and shall cause each of its Subsidiaries to, use commercially reasonable efforts to (1)(A) operate the Company Vessels, or cause the Company Vessels to be operated, (i) in a customary manner consistent with past practice, (ii) in accordance with the requirements of the class and flag state of each of the Company Vessels and the applicable manager’s safety management systems and (iii) in compliance with the requirements of port states with which each Company Vessel trades and (B) in the ordinary course of business maintain the Company Vessels, or cause the Company Vessels to be maintained, in good working condition and (2) use commercially reasonable efforts to preserve substantially intact its business, organization, assets and properties, and (3) use commercially reasonable efforts to preserve in all material respects its relationships with any customers, suppliers and any other Persons with which it has material business relations; provided, however, that no action by the Company or its Subsidiaries with respect to matters specifically addressed by any provision of Section 6.01(b) shall be deemed a breach of this sentence unless such action constitutes a breach of such provision of Section 6.01(b), and (b) shall not, and shall not permit any of its Subsidiaries to:

  • Conduct of Third Party Claims 11.4.1 If the matter or circumstance that may give rise to a claim against a Seller under this Agreement or any relevant Local Transfer Document for breach of any Seller’s Warranty (other than a Tax Warranty) is a result of or in connection with a claim by a third party (a “Third Party Claim”) then:

  • Conduct of Research Program Each Party:

  • Conduct of Research The Parties shall use Diligent Efforts to conduct their respective tasks, as assigned under the Research Plan, throughout the Mode of Action Program and shall conduct the Mode of Action Program in good scientific manner, and in compliance in all material respects with the requirements of applicable laws, rules and regulations and all applicable good laboratory practices to attempt to achieve their objectives efficiently and expeditiously.

  • Conduct of Business The business of the Company and its Subsidiaries shall not be conducted in violation of any law, ordinance or regulation of any governmental entity, except where such violations would not result, either individually or in the aggregate, in a Material Adverse Effect.

  • Conduct of Business and Maintenance of Existence Continue to engage in business of the same general type as now conducted by it and preserve, renew and keep in full force and effect its corporate existence and take all reasonable action to maintain all rights, privileges and franchises necessary or desirable in the normal conduct of its business except as otherwise permitted pursuant to subsection 8.5; comply with all Contractual Obligations and Requirements of Law except to the extent that failure to comply therewith could not, in the aggregate, be reasonably expected to have a Material Adverse Effect.

  • Conduct of Claims 31.6.1 The Indemnifying Party may at its own expense and with the assistance and co-operation of the Indemnified Party have the conduct of the Third Party Claim including its settlement and the Indemnified Party will not, unless the Indemnifying Party has failed to resolve the Third Party Claim within a reasonable period (and the Indemnified Party has notified the Indemnifying Party in writing that it is of the opinion that such reasonable period has expired), take any action to settle or pursue the Third Party Claim

  • Conduct of a Meeting The General Partner shall have full power and authority concerning the manner of conducting any meeting of the Limited Partners or solicitation of approvals in writing, including the determination of Persons entitled to vote, the existence of a quorum, the satisfaction of the requirements of Section 13.4, the conduct of voting, the validity and effect of any proxies and the determination of any controversies, votes or challenges arising in connection with or during the meeting or voting. The General Partner shall designate a Person to serve as chairman of any meeting and shall further designate a Person to take the minutes of any meeting. All minutes shall be kept with the records of the Partnership maintained by the General Partner. The General Partner may make such other regulations consistent with applicable law and this Agreement as it may deem advisable concerning the conduct of any meeting of the Limited Partners or solicitation of approvals in writing, including regulations in regard to the appointment of proxies, the appointment and duties of inspectors of votes and approvals, the submission and examination of proxies and other evidence of the right to vote, and the revocation of approvals in writing.

Time is Money Join Law Insider Premium to draft better contracts faster.